Metabolic Effects of Selected Traditional and Alternative Sweeteners: A Narrative Review

Why This Paper Matters

If you formulate low-sugar foods, you have watched the sweetener debate move past calories. The real question now is how sweeteners act in the body. This narrative review in Nutrients (DOI: 10.3390/nu16050622) looks directly at that question. It compares the metabolic effects of selected traditional and alternative sweeteners, with a focus on gut hormones.

That focus matters for product development. Gut hormones like GLP-1, PYY, CCK, and GIP influence appetite, digestion, and insulin regulation. A sweetener that changes those signals could do more than replace sugar. It could change how the body responds to the food around it.

Background

Sugar consumption is linked to a range of adverse health effects, including overweight and type 2 diabetes. That link is not new. But it keeps driving food brands toward alternatives. The problem is that replacement sweeteners do not all behave the same way. Some pass through the gut without being absorbed. Others trigger hormonal responses that look helpful.

The review pulls together human evidence on these effects. It does not report a single new experiment. Instead, it organizes what is already known and highlights the sweeteners with the most favorable metabolic data.

What the Study Did

This is a narrative review, not a randomized trial. The authors selected studies on traditional and alternative sweeteners and assessed their metabolic effects. They placed special emphasis on gut hormone responses after acute intake.

The key comparisons are rooted in signaling. GLP-1 and PYY are often tied to satiety. CCK plays a role in digestion and fullness. GIP helps regulate insulin after glucose intake. By tracking these hormones, the review gives formulators a clearer picture of what a sweetener might trigger in real human digestion.

Key Findings

The central message is direct. Xylitol, erythritol, and D-allulose show promise as alternative sweeteners because of their favorable metabolic outcomes.

Erythritol stands out. Acute intragastric or oral doses of 10 to 75 g induced secretion of GLP-1, CCK, and PYY. GIP, however, was not affected. That is a useful distinction. It means erythritol does not simply copy the hormone pattern of glucose.

D-allulose—also known as allulose—also performed well. A 25 g dose raised GLP-1, PYY, and CCK levels in healthy normal-weight subjects. That is exactly the kind of acute signal formulators want to see.

Sweetener	Acute dose tested	Hormones increased	GIP response
Erythritol	10–75 g intragastric or oral	GLP-1, CCK, PYY	Not affected
D-allulose	25 g oral	GLP-1, PYY, CCK	Not reported in the cited evidence

Xylitol appears in the review as part of the promising group. The acute hormone data in the abstract evidence, however, are centered on erythritol and D-allulose.

What It Means for Manufacturers

This evidence gives formulators something concrete to work with. Erythritol and allulose are not just bulking agents. At high acute doses, they produce measurable gut hormone changes. That may matter for products positioned around satiety, sugar reduction, or metabolic response.

But dose is the catch. The erythritol studies used 10 to 75 g in a single acute setting. The allulose study used 25 g. Those amounts are far above what most single servings deliver. A beverage may contain 5 to 15 g of allulose. A bakery item might contain 3 to 10 g of erythritol. You cannot assume the same hormone response at those levels.

The GIP finding is also worth attention. Erythritol raised GLP-1, CCK, and PYY without affecting GIP. That pattern is different from glucose. For formulators, it suggests a potentially distinct metabolic signal. But it is an acute observation, not a long-term health claim.

FAQ

Do these hormone increases mean erythritol or allulose will make people feel full?

Not necessarily. The review reports acute biochemical changes, not subjective satiety scores. GLP-1, PYY, and CCK are linked to appetite regulation, but the studies cited here measured hormones, not eating behavior. Treat this as promising mechanistic evidence, not a proven satiety benefit.

Are the tested doses realistic for commercial products?

No. 10 to 75 g of erythritol is a large amount for one serving. So is 25 g of allulose. The effects were seen in acute experiments. If you want to make a claim about hormone response, you need product-specific data at your actual use level.

Does the review support using xylitol?

It places xylitol with erythritol and D-allulose as a promising alternative sweetener. The specific acute hormone evidence cited in the abstract, though, is strongest for erythritol and D-allulose. Xylitol is a candidate, but check the original literature before you build a product story around it.

The Practical Read

The review points toward a future where sweeteners are selected for their signaling effects, not just their sweetness. Erythritol and allulose have the clearest acute hormone data. Xylitol shares the promising label, but with less detail in this evidence. For B2B buyers, the practical step is simple: ask suppliers for human data at realistic serving sizes. Keep the 10–75 g and 25 g numbers in mind when you evaluate claims. The science is shifting from sugar calories to metabolic signals. This review gives you a map of where the evidence stands now.